SOAT1 and inflammatory bowel disease: Given the wide range of effector molecules that use the JAK/STAT pathways, the latter is becoming an increasingly attractive therapeutic target for a wide range of immune-mediated diseases beyond rheumatic and inflammatory bowel diseases.